©The Author(s) 2017.
World J Gastrointest Pharmacol Ther. May 6, 2017; 8(2): 103-113
Published online May 6, 2017. doi: 10.4292/wjgpt.v8.i2.103
Published online May 6, 2017. doi: 10.4292/wjgpt.v8.i2.103
Table 1 Author’s summary of the evidence for combination therapy
| Crohn’s disease | Ulcerative colitis | |||
| Clinical benefit | Pharmacokinetic/immunogenic benefit | Clinical benefit | Pharmacokinetic/immunogenic benefit | |
| IFX + AZA/6MP (treatment naïve) | + | + | + | + |
| IFX + AZA/6MP (step-up from immunomodulator monotherapy) | - | NA | NA | NA |
| IFX + MTX | +/- | + | NA | NA |
| ADA + IMM | +/- | +/- | NA | NA |
| VDZ + IMM | NA | + | NA | NA |
| Ustekinumab + | NA | NA | NA | NA |
| IMM | ||||
- Citation: Sultan KS, Berkowitz JC, Khan S. Combination therapy for inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2017; 8(2): 103-113
- URL: https://www.wjgnet.com/2150-5349/full/v8/i2/103.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v8.i2.103